




OPEN ACCESS

# Molecular characterisation and antibiotic susceptibility of meningococcal isolates from healthy men who have sex with men

Arianna Neri ,<sup>1</sup> Annapina Palmieri,<sup>1</sup> Grazia Prignano,<sup>2</sup> Massimo Giuliani,<sup>3</sup> Alessandra Latini,<sup>3</sup> Cecilia Fazio,<sup>1</sup> Paola Vacca,<sup>1</sup> Luigina Ambrosio,<sup>1</sup> Andrea Ciammaruconi,<sup>4</sup> Silvia Fillo,<sup>4</sup> Anna Anselmo,<sup>4</sup> Antonella Fortunato,<sup>4</sup> Romano Lista,<sup>4</sup> Paola Stefanelli<sup>1</sup>

<sup>1</sup>Department of Infectious Diseases, Istituto Superiore di Sanità, Roma, Italy

<sup>2</sup>Clinical Pathology and Microbiology Unit, IRCC San Gallicano Institute, Rome, Italy

<sup>3</sup>STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Istituto Dermatologico San Gallicano, Roma, Italy

<sup>4</sup>Scientific Department, Army Medical Center, Centro Studi e Ricerche di Sanità e Veterinaria dell' Esercito, Roma, Italy

## Correspondence to

Dr Arianna Neri, Department Infectious Diseases, Istituto Superiore di Sanità, Roma, Italy; arianna.neri@iss.it

AN and AP contributed equally.

Received 30 June 2021

Accepted 31 October 2021

Published Online First

17 November 2021



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Neri A, Palmieri A, Prignano G, et al. *Sex Transm Infect* 2022;**98**:420–426.

## ABSTRACT

**Objectives** To evaluate and characterise meningococcal carriage among healthy men who have sex with men (MSM) within a screening programme for *Neisseria gonorrhoeae* infection at the San Gallicano Dermatological Institute, Italy.

**Methods** A total of 441 MSM attending the STI/HIV Centre of the San Gallicano Institute, Rome, Italy, in 2016 were routinely screened for *N. gonorrhoeae* infection by pharyngeal and rectal swabs. *N. meningitidis* isolates were evaluated for antibiotic susceptibility and characterised by whole genome sequencing. Genetic relationships among the meningococcal carriage isolates were determined using core genome multilocus sequence typing analysis. The soluble domain of AniA (sAniA) protein expression by western blotting was also evaluated.

**Results** A total of 62 (14.1%, 95% CI 11.1 to 17.6) carriage meningococci were found among 441 MSM. Forty-three viable *N. meningitidis* isolates were cultivated (42 from pharyngeal and 1 from rectal swabs). All the viable isolates were susceptible to cefotaxime, ceftriaxone, ciprofloxacin and rifampicin. Four isolates were penicillin G-resistant and 73% of those penicillin G-susceptible showed a minimum inhibitory concentration from 0.064 µg/mL to 0.25 µg/mL. Serogroup B was the most frequent (44.2%), followed by Z (16.3%), E (9.3%), and Y and W (2.3%), respectively. Multilocus sequence typing analysis identified 29 sequence types belonging to 12 clonal complexes. The sAniA protein was expressed in 8 out of 28 (29%) screened meningococcal carriage isolates.

**Conclusions** Serogroup B meningococcal carriage identified from oral and anal specimens among healthy MSM was the most frequent serogroup identified in this study. Molecular evaluation revealed a degree of similarity among strains belonging to the same clonal complex.

## INTRODUCTION

*Neisseria meningitidis* (Gram-negative diplococcus) is responsible globally for invasive meningococcal disease (IMD), in particular septicaemia and meningitis. Humans are the only hosts of *N. meningitidis* and can carry them harmlessly in the pharynx.<sup>1</sup> *N. meningitidis* can be transmitted through respiratory droplets from patients with IMD or from carriers.<sup>1</sup>

*N. meningitidis* is transmitted from person to person, and close contact with a healthy carrier can facilitate the spread of the bacteria to susceptible individuals.<sup>2</sup> Meningococcal carriage was estimated to occur in 10% of the general population, with most people becoming a carrier multiple times in their lifetime and may carry the bacteria for several months.<sup>1</sup> Meningococcal carriage increases in teenagers, with peak in young adults at 24%–25%.<sup>3</sup> Carriage status increases in smokers, closed and semiclosed populations, such as military recruits and university students, and in household contacts of a case of meningococcal disease.<sup>4,5</sup>

Meningococci can cross the epithelial barrier of the pharynx and gain access to the bloodstream, causing septicaemia. Moreover, it can penetrate the blood–brain barrier, giving rise to meningitis.<sup>2</sup>

The human pharynx remains the site preferentially colonised by *N. meningitidis*. Although *N. meningitidis* is an aerobic bacterium, it can respond to oxygen limitation condition by inducing activation of the alternative pathway of denitrification, which is initiated by the copper-containing nitrite reductase (AniA).<sup>6</sup> Therefore, occasionally urogenital and rectal meningococcal colonisation has been reported, with evidence of transmission between sexual partners involving the pharynx, urogenital tract and rectum.<sup>7</sup> Molecular characterisation studies have been carried out to understand the epidemiology and the spread of this invasive meningococcal population.<sup>8,9</sup> Outbreaks of IMD among men who have sex with men (MSM) have been reported<sup>10–13</sup>; however, few data are available on meningococcal carriage in MSM.<sup>14,15</sup>

Based on a screening programme for *N. gonorrhoeae* conducted during 2016 at the San Gallicano Institute, Rome, Italy, we evaluated the prevalence of *N. meningitidis* carriage isolates among healthy MSM, and the antimicrobial susceptibility and the molecular characteristics, by whole genome sequencing (WGS), and the expression of AniA protein among the analysed isolates.

## MATERIALS AND METHODS

### Study population and sample management

MSM attending, from January to December 2016, the STI/HIV Centre of the San Gallicano Dermatological Institute Hospital, Rome, Italy, were

screened for *N. gonorrhoeae* infection by pharyngeal and rectal swabs. *N. meningitidis* isolates from the same plates used for *N. gonorrhoeae* growth were identified. All meningococcal isolates, with a pseudoanonymous identification (ID) code, were sent to the National Reference Laboratory (NRL) for IMD at the Istituto Superiore di Sanità for further characterisation.

### Antimicrobial susceptibility test

Susceptibility to cefotaxime, ceftriaxone, ciprofloxacin, penicillin G and rifampicin was determined on all viable meningococcal carriage isolates using the minimum inhibitory concentration (MIC) test strip method (Liofilchem, Italy) on Mueller-Hinton agar (Thermo Scientific, USA), supplemented with 5% sheep blood. The breakpoints were those recommended by the European Committee on Antimicrobial Susceptibility Testing version 11.0 (1 January 2021; <http://eucast.org/>).

### Beta-lactamase test

The presence of the bacterial enzyme beta-lactamase was determined on all viable *N. meningitidis* isolates by rapid acid metric stick method (Oxoid, Italy) on IsoVitaleX 2% Thayer-Martin agar plate incubated overnight in 5% carbon dioxide (CO<sub>2</sub>) atmosphere at 37°C.

### Molecular characterisation

#### Genomic DNA extraction and WGS

Genomic DNA from cultivated meningococcal isolates (n=43) was extracted using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and was sent to the Army Medical Center Scientific Department for WGS. For each isolate, 1 ng of DNA was used to prepare the sequencing libraries, following the Nextera XT DNA protocol, according to the manufacturer's instructions (Illumina, California, USA). WGS was performed on meningococcal carriage isolates using Illumina MiSeq Sequencer Kit (V.3; 600 cycles). On average, 1.9 million paired-end reads were obtained for each sample. A first quality check of the raw sequence data was performed using FastQC.<sup>16</sup> Reads were trimmed to keep high-quality bases (Q score >25) using the Sickle V.1.33 software.<sup>17</sup> Sickle is a sliding-window, adaptive, quality-based trimming tool for FastQ files (V.1.33 software; available at <https://github.com/najoshi/sickle>). De novo assembly was carried out with the ABySS V.1.5.2 software (k parameter=63).<sup>18</sup> Contigs longer than 500 bp were selected using an ad hoc script and kept for further analysis. The final assembly ranged from 92 to 847 (median=211) contigs per sample covering ~2.2 Mb of the *N. meningitidis* genome.

#### Genome analysis

Of the 43 genomes from carriage isolates, only 32 were uploaded to the PubMLST Neisseria database (<http://pubmlst.org/neisseria/>). Genogroup definition, PorA and FetA typing, and multilocus sequence typing (MLST) were determined through the meningococcal typing website (<http://pubmlst.org/neisseria/>). Such information defined the finetype and the genotype as follows: genogroup: PorA(1.)VR1,VR2:FetA(F) VR:ST(cc).

WGS was used to identify *penA* and *rpoB* alleles, serogroup B vaccine antigen variants, and *aniA* allele.

Genomes were compared by means of the Bacterial Isolate Genome Sequence Database (BIGSdb) Genome Comparator Tool<sup>19</sup> within the PubMLST Neisseria database through gene-by-gene analysis. Phylogenetic analysis was performed using the *N. meningitidis* core genome MLST (cgMLST) scheme

(1605 loci)<sup>20</sup> on 32 carriage isolates of this study, plus 7 invasive meningococci isolated during the study period (2016) in Rome and collected by the NRL within the National Surveillance System for IMD. These invasive meningococci were two serogroup B/cc1572 (ID41657 and ID52942), one serogroup B/cc32 (ID41658), one serogroup B/cc213 (ID52946), two serogroup C/cc11 (ID52933 and ID52934), and one serogroup C/cc334 (ID52961).

Incomplete loci were removed automatically from the distance matrix calculation for the neighbour-net graphs. The resulting output distance matrix was used to generate neighbour-net networks using SplitsTree4 software (V.4.13.1).

### Western blotting

To determine the expression of AniA protein, western blotting assay was performed on a subsample of 28 meningococcal carriage isolates, according to previously described method, with minor modifications.<sup>21</sup> A polyclonal antiserum (Bio-Fab Research, Italy) raised against the soluble domain of AniA protein (sAniA) of *N. meningitidis* serogroup B reference strain MC58 was used for experiments.

Meningococcal isolates were cultured in standard growth conditions at 37°C with 5% CO<sub>2</sub> on IsoVitaleX 2% Thayer-Martin plates. Whole cell lysates and supernatants were prepared with 5% Laemmli buffer. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on 12% polyacrylamide gel. Polyclonal rabbit antiserum against AniA protein was used as primary antibody at 1:1000 dilution, and the anti-rabbit IgG conjugated to alkaline phosphatase (Merck Life Science, Italy) was used as secondary antibody at 1:15 000 dilution.

Finally, 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIP/NBT) Alkaline Phosphatase Substrate (Merck Life Science) was used to visualise the sAniA protein. *N. meningitidis* MC58 strain was used as the control strain in all experiments.

## RESULTS

### Demographic and clinical data

Sixty-two (14.1%, 95% CI 11.1 to 17.6) *N. meningitidis* isolates were identified from 441 MSM. Among them, 43 viable *N. meningitidis* isolates, 42 from pharyngeal and 1 from rectal swabs, were analysed. The median age of the subjects was 36 years (IQR: 23–52 years). All except for two subjects were Italians and confirmed as negative for other STIs.

### Antimicrobial susceptibility

Antimicrobial susceptibility was performed on 37 out of 43 *N. meningitidis* carriage isolates. All of them were susceptible to cefotaxime, ceftriaxone, ciprofloxacin and rifampicin. Among the isolates susceptible to penicillin G (97%, 33 of 37), 27 showed MIC for penicillin G higher than 0.064 µg/mL (0.064 µg/mL < MIC < 0.25 µg/mL) and 4 were penicillin G-resistant (Pen<sup>R</sup>), with MIC values ranging from 0.38 µg/mL to 0.50 µg/mL. All four penicillin-resistant isolates were beta-lactamase-negative.

### Molecular characterisation

The meningococcal genogroup was identified in the 43 meningococcal carriage isolates, with 19 (44%) serogroup B (MenB), 7 (16%) MenZ, 4 (9%) MenE, 1 MenY and 1 MenW. A total of seven isolates (16%) were *cnl* and four (9%) were non-groupable (NG).

**Table 1** Molecular characteristics of 43 meningococcal carriage isolates

Serogroup	Identification ( <a href="http://pubmlst.org/Neisseria">http://pubmlst.org/Neisseria</a> )	Clonal complex	Sequence type	Finetype	Number of isolates
B (n=19)	61173/–	32	7460	P1.18-1,30-5:F3-3	2
	–	41/44	1097	P1.17-7,23:F1-5	1
	61167	41/44	1103	P1.7-2,13-1:F1-88	1
	61160	162	2153	P1.19,14:F1-62	1
	63041	213	213	P1.22,14:F5-5	1
	61171	269	13747	P1.19,15-3:F1-5	1
	61161/61188/–	461	1946	P1.19-2,13-1:F3-9	3
	61163	1572	1572	P1.7-12,14:F3-9	1
	61172	1572	12712	P1.7-12,14:F162	1
	61170	1572	1572	P1.7-12,14:F1-7	1
	61184	4821	3200	P1.17-6,23-6:F3-36	1
	63035	4821	3469	P1.17-6,23:F3-36	1
	–	na	897	P1.12-1,16-75-6:F1-12	1
	63034	na	11294	P1.12,16-11:F5-7	1
	61176	na	13506	P1.12,16-75:F1-5	1
	61186	na	13748	P1.12,13-43:F1-5	1
	cni (n=7)	61166	53	53	P1.7,30:F1-2
61165		162	2153	P1.18-1,30:F1-62	1
–		162	2153	P1.7-2,13-33:F1-62	1
61177		162	12267	P1.22,14-12:F3-29	1
–		1136	1136	P1.18-4,3:F4-1	2
61187		na	13749	P1.22,14-13:F5-7	1
Z (n=7)	61183	na	10866	P1.22-4,14-6:F5-7	1
	61164	na	12943	P1.21-19,16-16:F5-7	1
	61174/61178/63038/61182	na	13741	P1.21-19,16-16:F5-7	4
	61169	na	13746	P1.21-19,16-16:F5-7	1
E (n=4)	–	1157	1157	P1.21-7,16-46:ΔF	1
	61180/61181/63037	na	13740	P1.12-8,16-8:F5-81	3
NG (n=4)	61168	162	2153	P1.19-5,14:F1-62	1
	–	na	6119	P1.12-8,16-8:F16-119	1
	61175	na	13568	P1.19-1,13-9:F1-8	1
	61162	na	na	P1.12,16-11:F1-5	1
Y (n=1)	61179	174	1466	P1.21, 16:F3-7	1
W (n=1)	61185	11	11	P1.1.5,2:F1-1	1

The table was created by the authors.

'–' indicates no genome available.

'na' indicates not assigned to any known clonal complex.

cni, capsule null locus; NG, non-groupable; ΔF, *fetA* gene deletion.


MLST identified 29 sequence types (STs) belonging to 12 clonal complexes (cc), of which cc162 (n=5, 42%) and cc461 (n=3, 25%) were the most frequent. Twelve sequence types, identified in 12 isolates (4 MenB, 4 MenZ, 2 NG, 1 MenE and 1 *cni*), were not designed to any known clonal complex and were classified as 'not assigned' (na) (table 1).

Among the MenB isolates, cc461 (n=3), cc1572 (n=3), cc32 (n=2), cc41/cc44 (n=2), cc4821 (n=2), cc162 (n=1), cc213 (n=1) and cc269 (n=1) were found. Only one of the four MenE isolates belonged to cc1157; the MenW isolate belonged to cc11 and the MenY isolate belonged to cc174. Among the *cni* isolates, cc162 (n=3), cc1136 (n=2) and cc53 (n=1) were identified (table 1). A total of 29 PorA types and 16 FetA variants were identified. The most frequent PorA types were P1.7-12,14 (3 of 43, 7%) and P1.21-19,16-16 (3 of 43, 7%). The predominant FetA variant was F1-62 (6 of 43, 14%) and F5-7 (6 of 43, 14%). One carriage isolate (1 of 43, 2.3%) gave negative PCR results for *fetA* gene (table 1).

### Meningococcal serogroup B vaccine antigen variants

4CMenB variant family 2/Pfizer subfamily A (fHbp-2/A) was the most represented (49%, 21 of 43), followed by variant family 1/Pfizer subfamily B (fHbp-1/B) (21%, 9 of 43) and variant family 3/subfamily A (fHbp-3/A) (7%, 3 of 43). Figure 1 shows the fHbp peptides distributed per clonal complex. In all carriage isolates, 19 Neisserial Heparin Binding Antigen (NHBA) peptides were found (figure 2). The most frequent NHBA peptides identified were peptide 20 identified in 7 isolates (5 *cni*/cc162; 2 MenB/cc1572); peptide 101 identified in 6 MenZ isolates (4 ST-13741; 1 ST-12943; 1 ST-13746); and NHBA peptide 1172 was detected in 4 isolates (3 MenE ST-13740 and 1 NG ST-6119) (table 1).

The *nadA* gene was found in eight isolates: NadA-1 in two MenB/cc32 isolates; NadA-8 in three MenZ/ST-13741 isolates, in one MenZ/ST-13746 isolate and in one MenW/cc11 isolate; and NadA-79 in one MenB/cc213 isolate. The



**Figure 1** Distribution of fHbp peptides by clonal complex (for each the variant is indicated for each fHbp peptide is indicated its variant). 'na' indicates not assigned to any known clonal complex in the MLST website. cc, clonal complex; MLST, multilocus sequence typing.

remaining isolates (35 of 43, 81%) resulted negative to the *nadA* gene.

Twenty-one PorAVR2 peptides were identified in 34 isolates. The most frequent PorAVR2 peptide was P1.14 (n=6), followed by P1.16-6 (n=3). Six PorA VR2 peptides (P1.16-75, P1.23, P1.30, P1.13-1, P1.13-9, P1.16-11) occurred twice and the remaining 15 PorAVR2 peptides occurred once.

### *penA* and *rpoB* alleles


Identification of *penA* and *rpoB* alleles was performed on 43 meningococcal carriage isolates. A total of 16 different *penA* alleles were found. Four *penA* alleles were identified in the four isolates resistant to penicillin G, of which *penA179*, *penA209* and *penA295* were identified in the isolate with MIC of 0.38 µg/mL and *penA327* in the isolate with MIC of 0.5 µg/mL.

The two prevalent *rpoB* alleles were *rpoB21* (10 of 43, 23%) and *rpoB28* (9 of 43, 21%), followed by *rpoB2* (5 of 43, 12%), *rpoB5* (4 of 43, 9%), *rpoB1* (3 of 43, 7%), *rpoB4* (3 of 43, 7%), *rpoB207* (3 of 43, 7%), *rpoB18* (3 of 43, 7%) and *rpoB85* (2 of 43, 5%). *rpoB8*, *rpoB9*, *rpoB34* and *rpoB42* were detected each one in one isolate.


### Core genome multilocus sequence typing

Thirty-two genomes of 43 meningococcal carriage isolates and 7 invasive meningococcal genomes were analysed using cgMLST to characterise the phylogenetic correlations. The cgMLST analysis included 1269 of the 1605 core genome loci, excluding 336 incomplete loci. All meningococcal carriage and invasive genomes were distributed based on clonal complex or sequence type (figure 3). The genome comparison revealed similarities and close relationships among genomes from meningococcal carriage isolates. The two MenZ/ST-13741 (ID63038 and ID61182) had no different loci. Moreover, these two genomes differed by 15 loci with ID61178 (MenZ/ST-13741) and by 55 loci with ID61174 (MenZ/ST-13741). Other two MenZ ID61164 (ST-12943) and ID61169 (ST-13746) showed a distance of 17 loci. The three MenE/ST-13740 genomes showed close relationships: between ID63037 and ID61180, isolated from the pharynx and rectal swabs of the same patient, respectively, a distance of 41 different loci were found. Moreover, ID61180 showed only three different loci with ID61181.

The two cc162 genomes from carriage isolates (ID61160 and ID61168) revealed a small genetic distance of 19 loci.



**Figure 2** Distribution of NHBA peptides by clonal complex (cc).



**Figure 3** Neighbour-net network based on comparison of *Neisseria meningitidis* carriage ( $n=32$ ) and invasive (red dots,  $n=7$ ) genomes by cgMLST. For each genome the identification (ID) code from <http://pubmlst.org/Neisseria> is reported. The main clusters among carriage genomes are highlighted by circles. The scale bar represents the number of variant loci. 'na' indicates not assigned to any known clonal complex. cc, clonal complex; cgMLST, core genome multilocus sequence typing.

We observed that meningococcal carriage and invasive genomes, belonging to the same clonal complex, grouped together (figure 3). In particular, the two MenB/cc213 genomes (ID63041 from carriage isolate and ID52946 from invasive isolate) clustered together with a distance of 37 loci.

### Western blotting

As shown in table 2, 8 out of 28 (29%) screened meningococcal carriage isolates on western blot assay for the expression of sAniA showed the ~55 kDa sAniA form. These isolates were MenE ( $n=3$ ), MenB ( $n=2$ ), MenY ( $n=1$ ), MenZ ( $n=1$ ) and *cnl* ( $n=1$ ). The molecular characterisation evidenced six *aniA* alleles: 6, 11, 53, 229, 673 and 675. The *aniA* allele 675 ( $n=3$ ) was found in three MenE/ST-13740 genomes (na).

AniA protein was not expressed in the remaining 20 isolates (71%). In four meningococcal isolates, the *aniA* gene was missing. In one isolate belonging to the genotype W:P1.5,2:F1-1:ST-11 (cc11), a premature stop codon was found in the *aniA* gene (*aniA* allele 1) (table 2). The remaining 15 isolates harboured an intact *aniA* gene but did not express the protein.

### DISCUSSION

Isolation of invasive *N. meningitidis* from MSM has been already reported in several studies,<sup>11–13</sup> and an increasing number of outbreaks of meningococcal disease has been reported in Europe and in the USA in the same population.<sup>13–15 22 23</sup>

In this study, a cohort of MSM participants at a screening programme for *N. gonorrhoeae* infection were considered for the presence of *N. meningitidis* in the oropharynx and urogenital tracts.

The proportion of meningococcal carriage (14.1%) was consistent with that already described by Carlin *et al.*<sup>14</sup> While invasive meningococcal isolates from MSM found in Europe

were predominantly serogroup C,<sup>11</sup> this serogroup was absent among our carriage isolates. Majority of the carried meningococci were of serogroup B, one of the two most frequent serogroups of invasive meningococcal isolates circulating in Italy in the same period (<https://www.iss.it/sn-mbi-rapporti-iss>).

The clonal complexes of the carriage meningococci analysed accounted for the most frequently clonal complexes reported in healthy carriers.<sup>3 4</sup> Only three carriage isolates belonged to the hypervirulent clonal complexes (cc41, cc44 and cc11), mainly associated with invasive meningococci circulating in the country.<sup>24</sup>

Phylogenetic analysis to investigate the genetic relationships among these carriage and invasive meningococci, isolated in Rome in the same period, revealed clusters including isolates belonging to the same clonal complexes regardless of the invasiveness. We can hypothesise that carriage meningococci belonging to a hypervirulent clonal complex may be widely transmitted in the MSM community and may determine an invasive disease. Moreover, the high degree of genetic similarity for carriage isolates belonging to the same clonal complex may suggest the presence of a cluster of those isolates among the screened MSM.

Evaluation of antibiotic susceptibility revealed a high proportion of carriage isolates with reduced susceptibility to penicillin G and resistance to penicillin G in four carriage isolates. Among the resistant carriage isolates to penicillin G, one *penA327* allele was already described in the meningococcal isolates from the outbreak of IMD among MSM.<sup>25</sup> This allele is identical to the allele *penAXXXIV*, associated with resistance to third-generation cephalosporin and reduced susceptibility to cefotaxime in *N. gonorrhoeae*.<sup>25</sup> However, *penA327* allele was associated with resistance to penicillin G, but not with resistance to cephalosporin and reduced susceptibility to cefotaxime. These results correlate with the possibility of a genetic exchange among

**Table 2** Genogroup, genotype, *aniA* allele and AniA expression detected in 28 meningococcal carriage isolates from men who have sex with men

Genogroup	Identification ( <a href="http://pubmlst.org/Neisseria">http://pubmlst.org/Neisseria</a> )	Genotype	<i>aniA</i> allele	AniA protein
B (n=12)	61173	B:P1.18-1,30-5:F3-3:ST-7460 (cc32)	229	+
	61167	B:P1.7-2,13-1:F1-88:ST-1103 (41/44)	2	-
	63041	B:P1.22,14:F5-5:ST-213 (cc213)	19	-
	61171	B:P1.19,15-3:F1-5:ST-13747 (cc269)	4	-
	61161	B:P1.19-2,13-1:F3-9:ST-1946 (cc461)	673	+
	61163	B:P1.7-12,14:F3-9:ST-1572 (cc1572)	X	-
	61170	B:P1.7-12,14:F3-9:ST-1572 (cc1572)	X	-
	61172	B:P1.7-12,14:F162:ST-12712 (cc1572)	X	-
	61184	B:P1.17-6,23-6:F3-36:ST-3200 (cc4821)	228	-
	63035	B:P1.17-6,23:F3-36:ST-3469 (cc4821)	8	-
	63034	B:P1.12,16-11:F5-7:ST-11294 (UNK)	4	-
	61176	B:P1.12,16-75:F1-5:ST-13506 (UNK)	674	-
cni (n=3)	61166	cni:P1.7,30:F1-2:ST-53 (cc53)	17	-
	61165	cni:P1.18-1,30:F1-62:ST-2153 (cc162)	6	+
	61187	cni:P1.22,14-13:F5-7:ST-13749 (UNK)	11	-
Z (n=6)	61183	Z:P1.22-4,14-6:F5-7-119:ST-10866 (UNK)	11	+
	61164	Z:P1.21-19,16-16:F5-7:ST-12943 (UNK)	240	-
	61174	Z:P1.21-19,16-16:F5-7:ST-13741 (UNK)	240	-
	63038	Z:P1.21-19,16-16:F5-7:ST-13741 (UNK)	240	-
	61182	Z:P1.21-19,16-16:F5-7:ST-13741 (UNK)	240	-
	61169	Z:P1.21-19,16-16:F5-7:ST-13746 (UNK)	240	-
E (n=3)	61180	E:P1.12-8,16-8:F5-81:ST-13740 (UNK)	675	+
	61181	E:P1.12-8,16-8:F5-81:ST-13740 (UNK)	675	+
	63037	E:P1.12-8,16-8:F5-81:ST-13740 (UNK)	675	+
NG (n=2)	61168	NG:P1.19-5,14:F1-62:ST-2153 (cc162)	6	-
	61175	NG:P1.19-1,13-9:F1-8:ST-13568 (UNK)	X	-
Y (n=1)	61179	Y:P1.21,16:F3-7:ST-1466 (cc174)	53	+
W (n=1)	61185	W:P1.1.5,2:F1-1:ST-11 (cc11)	1	-

The table was created by the authors.  
*aniA* with premature stop codon.  
 cni, capsule null locus; NG, non-groupable; UNK, unknown; X, missing *aniA* gene.

gonococci and carriage meningococci in the pharynx, as already described in MSM.<sup>26</sup> Because of this evidence, all the individuals identified as meningococcal carriers were recalled at the San Gallicano Dermatological Institute and subjected to chemoprophylaxis with ceftriaxone 1 g as a single intramuscular dose. Ceftriaxone was used based on the antibiotic susceptibility of the isolates and in agreement with the guidelines for chemoprophylaxis in contacts of patients with invasive disease. In addition, many of the meningococcal carriers had been already treated with ceftriaxone for previous *N. gonorrhoeae* infection without adverse events. Ceftriaxone can be used at any age and was thus advantageous given the wide age range of the subjects to be treated. Moreover, to reduce meningococcal carriage and the risk of invasive disease, every effort was made to enhance vaccination coverage for *N. meningitidis* among MSM.<sup>27</sup>

The copper-containing nitrate reductase, AniA, plays a significant role in catalysing the conversion of nitrite to nitric oxide, which is subsequently reduced to nitrous oxide by NorB.<sup>28</sup> The ability of *N. meningitidis* to grow under oxygen limitation through denitrification pathway has facilitated its adaptation to environments where oxygen availability is variable.<sup>21</sup> While this pathway is crucial to the survival of *N. gonorrhoeae*, the denitrification pathway is not essential in the survival of *N. meningitidis* in the nasopharynx.<sup>29</sup> Hereby, 29% of the carriage meningococci expressed the AniA protein except for 5 isolates, lacking the gene or with a premature stop codon in the first half of the nucleotide

sequence, while the other 15 meningococcal isolates were unable to express the protein despite the presence of the entire *aniA* gene. Since the expression of meningococcal AniA protein is under the control of a complex regulatory network involving multiple transcriptional regulators, it is possible to hypothesise that nucleotide polymorphisms in the putative regulator sites explain the inability of these meningococci to produce AniA.<sup>29</sup>

A report published by Taha *et al*<sup>11</sup> revealed that meningococcal isolates collected from the urethra harboured a functional AniA, but were defective for fHbp due to a premature stop codon. This phenotype (AniA<sup>+</sup>, fHbp<sup>-</sup>) could reflect an adaptation and selection of meningococci which colonised uncommon sites, such as the urethra and the rectum.<sup>11</sup> This result differs from the data here presented, with majority of the isolates from the pharynx harbouring an entire *fHbp* gene.

## CONCLUSION

Our findings, together with data collected from the literature, underline the appropriateness of meningococcal screening in the MSM community, to adopt the opportune clinical practices and public health action.

Moreover, our study highlights the need to further characterise meningococci isolated from the pharyngeal and anorectal tracts, particularly in terms of the new genes they can acquire, including those classified as antibiotic resistance determinants.

It is important to identify the meningococcal serogroup to assess how and if these strains may be preventable by vaccination. Information on serogroups could be essential in the implementation of public health control measures in case of an outbreak, including vaccination, which has been reported to manage an outbreak of IMD of serogroup C in MSM in New York City.<sup>23</sup>

### Key messages

- ⇒ Serogroup B was the main serogroup identified among the meningococci isolated from healthy men who have sex with men (MSM) in this study.
- ⇒ The acquisition of *penA327* allele in one penicillin G-resistant meningococcal carriage isolate highlights the possibility of exchange, in the pharynx, of genetic materials among meningococci and gonococci.
- ⇒ This study underlines the importance of pharyngeal and rectal swab screening to detect *Neisseria meningitidis* among MSM.

**Handling editor** Federico Garcia

**Twitter** Massimo Giuliani @gijumas3

**Acknowledgements** This publication made use of the PubMLST website (<https://pubmlst.org/>) and sited at the University of Oxford. The development of this website was funded by the Wellcome Trust. We thank Keith Jolley from the University of Oxford for editing the text.

**Contributors** PS, GP and MG designed the study. AN and AP wrote the first draft of the manuscript. AN was the author responsible for the overall content as the guarantor. AP, AN, CF, PV and LA performed the molecular analysis. AC, SF, AA, AF and RL carried out the whole genome sequencing. All authors reviewed and commented critically to the manuscript and gave final approval to submit for publication.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** The study was cleared by the Institutional Ethics Committee, San Gallicano Dermatological Institute, IRCSS IFO Section-Fondazione GB Bietti (CE/626/11, 28-11-2011).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information. All data relevant to the study are included in the article.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

### ORCID iD

Arianna Neri <http://orcid.org/0000-0001-5748-880X>

### REFERENCES

- 1 Hill DJ, Griffiths NJ, Borodina E, *et al.* Cellular and molecular biology of *Neisseria meningitidis* colonization and invasive disease. *Clin Sci* 2010;118:547–64.
- 2 Caugant DA. Genetics and evolution of *Neisseria meningitidis*: importance for the epidemiology of meningococcal disease. *Infect Genet Evol* 2008;8:558–65.
- 3 Neri A, Fazio C, Ambrosio L, *et al.* Carriage meningococcal isolates with capsule null locus dominate among high school students in a non-endemic period, Italy, 2012–2013. *Int J Med Microbiol* 2019;309:182–8.
- 4 Bogaert D, Hermans PWM, Boelens H, *et al.* Epidemiology of nasopharyngeal carriage of *Neisseria meningitidis* in healthy Dutch children. *Clin Infect Dis* 2005;40:899–902.
- 5 Tryfinopoulou K, Kesanopoulos K, Xirogianni A, *et al.* Meningococcal carriage in military recruits and university students during the pre MenB vaccination era in Greece (2014–2015). *PLoS One* 2016;11:e0167404.
- 6 Anjum MF, Stevanin TM, Read RC, *et al.* Nitric oxide metabolism in *Neisseria meningitidis*. *J Bacteriol* 2002;184:2987–93.
- 7 Ladhani SN, Lucidarme J, Parikh SR, *et al.* Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to *Neisseria meningitidis*. *Lancet* 2020;395:1865–77.
- 8 Odegaard K, Gundersen T. Isolation of *Neisseria meningitidis* in urogenital/rectal infections. *Acta Derm Venereol* 1977;57:173–6.
- 9 Chapel TA, Gatewood C, Keane MB. *Neisseria meningitidis* in the anal canal of homosexual men. *J Infect Dis* 1977;136:810–2.
- 10 Kanemitsu N, Hayashi I, Satoh N, *et al.* Acute urethritis caused by *Neisseria meningitidis*. *Int J Urol* 2003;10:346–7.
- 11 Taha M-K, Claus H, Lappann M, *et al.* Evolutionary events associated with an outbreak of meningococcal disease in men who have sex with men. *PLoS One* 2016;11:e0154047.
- 12 Marcus U, Vogel U, Schubert A, *et al.* A cluster of invasive meningococcal disease in young men who have sex with men in Berlin, October 2012 to may 2013. *Euro Surveill* 2013;18. doi:10.2807/1560-7917.ES2013.18.28.20523. [Epub ahead of print: 11 Jul 2013].
- 13 Weiss D, Varma JK. Control of recent community-based outbreaks of invasive meningococcal disease in men who have sex with men in Europe and the United States. *Euro Surveill* 2013;18:es2013.18.28.20522.
- 14 Carlin EM, Hannan M, Walsh J, *et al.* Nasopharyngeal flora in HIV seropositive men who have sex with men. *Genitourin Med* 1997;73:477–80.
- 15 Tinggaard M, Slotved H-C, Fuursted K, *et al.* Oral and anal carriage of *Neisseria meningitidis* among sexually active HIV-infected men who have sex with men in Denmark 2014–15. *Int J Infect Dis* 2021;105:337–44.
- 16 Andrews S. *Fast Qc a quality control tool for high throughput sequence data*. Cambridge: Babraham Institute, 2010. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc>
- 17 Fass JN, Joshi NA, Couvillion MT, *et al.* Genome-Scale analysis of programmed DNA elimination sites in *Tetrahymena thermophila*. *GB* 2011;1:515–22.
- 18 Simpson JT, Wong K, Jackman SD, *et al.* ABySS: a parallel assembler for short read sequence data. *Genome Res* 2009;19:1117–23.
- 19 Jolley KA, Maiden MCJ. BIGSdb: scalable analysis of bacterial genome variation at the population level. *BMC Bioinformatics* 2010;11:595.
- 20 KC M, Unemo M, Jeverica S. Genomic characterization of Urethritis-Associated *Neisseria meningitidis* shows that a wide range of *N. meningitidis* strains can cause urethritis. *J Clin Microbiol* 2017;55:3374–83.
- 21 Stefanelli P, Colotti G, Neri A, *et al.* Molecular characterization of nitrite reductase gene (*aniA*) and gene product in *Neisseria meningitidis* isolates: is *aniA* essential for meningococcal survival? *IUBMB Life* 2008;60:629–36.
- 22 Agrawal A, Jasdawal S, Agarwal A, *et al.* Fatal Waterhouse-Friderichsen syndrome due to serotype C *Neisseria meningitidis* in a young HIV negative MSM (men who have sex with men). *BMJ Case Rep* 2014;2014:bcr2014206295.
- 23 Kratz MM, Weiss D, Ridpath A, *et al.* Community-Based outbreak of *Neisseria meningitidis* serogroup C infection in men who have sex with men, New York City, New York, USA, 2010–2013. *Emerg Infect Dis* 2015;21:1379–86.
- 24 Ambrosio L, Neri A, Fazio C, *et al.* Genomic analysis of *Neisseria meningitidis* carriage isolates during an outbreak of serogroup C clonal complex 11, Tuscany, Italy. *PLoS One* 2019;14:e0217500.
- 25 Deghmane A-E, Hong E, Taha M-K. Emergence of meningococci with reduced susceptibility to third-generation cephalosporins. *J Antimicrob Chemother* 2017;72:95–8.
- 26 Zapun A, Morlot C, Taha M-K. Resistance to  $\beta$ -lactams in *Neisseria ssp* due to chromosomally encoded penicillin-binding proteins. *Antibiotics* 2016;5:35.
- 27 Zalmanovici Trestioreanu A, Fraser A, Gafter-Gvili A, *et al.* Antibiotics for preventing meningococcal infections. *Cochrane Database Syst Rev* 2013;2013:CD004785.
- 28 Barth KR, Isabella VM, Clark VL. Biochemical and genomic analysis of the denitrification pathway within the genus *Neisseria*. *Microbiology* 2009;155:4093–103.
- 29 Ku SC, Schulz BL, Power PM, *et al.* The pilin O-glycosylation pathway of pathogenic *Neisseria* is a general system that glycosylates AniA, an outer membrane nitrite reductase. *Biochem Biophys Res Commun* 2009;378:84–9.

## MICRO framework - A checklist of items that should be addressed in reports of studies involving human clinical microbiology data

[Core “must include” items are indicated by an asterisk]

Section	Item No	Recommendation	Completed Yes / No / NA	Page No
<b>Methods</b>				
<b>Study design</b>	1*	<b>Specimen types:</b> Describe the types of specimen included, i.e. clinical (e.g. blood cultures) or non-diagnostic surveillance (e.g. admission and other screening swabs to diagnose carriage). If specimens were obtained for diagnostic reasons, clinical syndromes should be described where possible, and specimens / isolates stratified by clinical syndrome.	Yes	4
	2*	<b>Sampling period:</b> State the collection timeframe for specimens yielding isolates for which data is reported, e.g. from MM/YY to MM/YY to be able to identify variability between seasons.	Yes	4
	3*	<b>Sampling strategy:</b> Describe the strategy for specimen collection, e.g. asymptomatic screening, sampling of all febrile patients, sampling at clinician discretion, sampling of specific patient groups, convenience sampling (e.g. use of isolates from an existing sample repository). Specify whether sampling followed routine clinical practice or was protocol driven. Classify specimens as from community-acquired (CAI) or hospital-acquired (HAI) infections. The definition of HAI used (e.g. HAI defined by specimen collection >48h after hospital admission) should be provided and should use ideally an international standard (e.g. US-Centers for Disease Control (1, 2)).	No	
	4	<b>Target organisms:</b> Explicitly state which organisms / organism groups were included in the report. Nomenclature should follow international standards (i.e. using approved genus / species names as summarised in the International Journal of Systematic and Evolutionary Microbiology). Lists of approved bacterial names can be downloaded from <a href="#">Prokaryotic Nomenclature Up-to-Date</a> and the <a href="#">List of Prokaryotic Names with Standing in Nomenclature</a> . Organisms considered contaminants should be listed, if appropriate (e.g. coagulase negative staphylococci or <i>Corynebacterium</i> spp. (3, 4)).	Yes	4
<b>Setting</b>	5*	<b>Geographical setting:</b> Describe the geographical distribution of specimens / patients from which isolates were obtained; at least to a country level, but preferably to a sub-national level or a geoposition.	Yes	4
	6*	<b>Clinical setting:</b> Describe the type and level of the healthcare facilities (e.g. primary, secondary, tertiary) from which specimens were obtained. If stating a microbiology laboratory, the centres served by the laboratory should be specified.	No	
<b>Laboratory work</b>	7	<b>Specimen processing:</b> If applicable, describe specimen collection and handling, processing and sub-culture methods for all types of specimen included. For example, if reporting AST results for blood culture and cerebrospinal fluid culture isolates, the processing of these specimens by the laboratory should be briefly explained, including how specimens are sub-cultured, the media used, incubation	Np	



		conditions and duration. A summary of specimen processing steps (e.g. pre-processing steps, nucleic acid extraction method (if applicable), amplification platform, contamination avoidance strategy) should be provided for molecular-only workflows (e.g. to detect <i>Mycobacterium tuberculosis</i> and rifampicin resistance using the Cepheid Xpert MTB / RIF system).		
	8*	<b>Target organism identification:</b> Details of identification methodology should be reported briefly. Where identification databases were used (e.g. bioMerieux API / bioMerieux VITEK-MS / Bruker Biotyper), the version should be specified. In general, all pathogens should be identified to species level. In the case of <i>Salmonella</i> species, organisms should be identified to at least the <i>S. Typhi</i> , <i>S. Paratyphi</i> , or non-typhoidal salmonella (NTS) level. Strain subtyping methods should be reported according to STROME-ID (5).	No	
	9*	<b>Antimicrobial susceptibility testing:</b> Describe the antimicrobial susceptibility testing methods used, internal quality control processes, and their interpretation, with reference to a recognised international standard – e.g. CLSI, EUCAST. Where an international standard was followed, the specific edition(s) of guidelines used should be referenced. Deviations from standard methodology should be described, along with evidence of validation. Handling of any changes to interpretative criteria during the sampling period should be documented. State whether the raw AST data (zone diameters and / or minimum inhibitory concentrations) were re-categorised with updated breakpoints or left as-is.	Yes	4
	10	<b>Additional tests performed to identify resistance mechanisms:</b> Describe the testing methods used for adjunctive / confirmatory antimicrobial susceptibility tests, such as enzymatic / molecular assays (e.g. Xpert MTB / RIF, mecA PCR) and inducible resistance assays, with reference to a recognised international standard, where available. Where an international standard was followed, the specific edition of guidelines used should be referenced. Deviations from standard methodology should be described, along with evidence of validation.	No	
	11*	<b>Antimicrobial resistance definitions:</b> Define resistance for each antimicrobial class (i.e. are isolates in the “intermediate” category included within “susceptible” or “resistant” or analysed as a distinct category). If using the term, define MDR (e.g. $\geq 1$ agent in $\geq 3$ classes tested). For each organism type, an MDR test panel must be defined, consisting of the minimum panel of individual antimicrobial agents / classes against which an isolate must be tested for that isolate to be considered tested for MDR status. Antimicrobials to which an organism is intrinsically resistant cannot be part of the test panel or contribute to MDR status (6, 7).	Yes	4
<b>Quality assurance</b>	12*	<b>External quality assurance:</b> State whether the microbiology laboratory participates in an external quality control programme and, if so, provide scheme details. Examples include the <a href="#">UK National External Quality Assurance Scheme</a> and the <a href="#">American College of Pathologists External Quality Assurance / Proficiency Testing Program</a> .	No	
	13	<b>Accreditation:</b> State whether the laboratory is accredited through a national or international body (e.g. the	No	

		International Standards Organisation, ISO) and specify which assays are covered in the accreditation.		
<b>Bias</b>	14*	<b>Duplicate and sequential isolates:</b> The strategy for accounting for duplicate and sequential isolates from the same patient should be clearly detailed. Duplicate isolates are multiple isolates of the same phenotypic organism (i.e. same species and same resistance profile) from the same patient on the same date cultured either from the same clinical specimen, or from two separate clinical specimens, such as blood and CSF. Sequential isolates are isolates of the same phenotypic organism from the same patient at different dates, such as blood cultures taken on different dates. Various strategies for the handling of duplicate and sequential isolates exist (8), and the strategy used should be transparent as it will bias pooled resistance results. For example, inclusion of all isolates (the 'all isolate strategy'), has been shown to shift pooled resistance proportions toward greater resistance, whilst inclusion of only the first isolate per patient (the 'first isolate strategy') or only the first isolate per infection episode (the 'episode-based strategy') will shift pooled results towards susceptibility.	<b>No</b>	
<b>Results</b>				
	15*	<b>Population:</b> Describe the demographics of the population from which clinical specimens and subsequent isolates have been obtained, disaggregating age and gender data.	<b>Yes</b>	<b>6</b>
	16*	<b>Denominators:</b> Patient and isolate denominators should be used appropriately to ensure clarity regarding the numbers included in each analysis. Of particular importance is the reporting of resistance where first- and second-line AST panels were used (i.e. not all isolates of a particular species were tested against all agents). For drugs where only a subset of isolates were tested, reporting of a percentage without the numbers of isolates tested / resistant may be highly misleading.	<b>Yes</b>	<b>6</b>
	17	<b>Site / place of acquisition:</b> AST data from CAI and HAI should be reported and analysed separately.	<b>No</b>	
	18*	<b>Reporting resistance proportions for single agent and class resistance:</b> Proportions of resistant isolates should be reported as number of isolates susceptible or resistant to a given antimicrobial agent / class out of actual number of isolates tested for susceptibility to that agent / class.	<b>Yes</b>	<b>6</b>
	19	<b>Reporting multidrug resistance proportions:</b> If defined, the proportion of MDR isolates should be expressed as the number of MDR isolates out of the number of isolates tested (i.e. the number undergoing the MDR test panel specific to that organism). Single agent / class resistance should be always be reported, regardless of MDR reporting.	<b>No</b>	
<b>Discussion</b>				
<b>Limitations</b>	20	Discuss any reasons why bias may have been introduced into the reported data, due to patient / specimen selection, isolation of organisms, or otherwise. Consider factors which may have either introduced bias into the types of organisms isolated or the antimicrobial susceptibility profiles, e.g. receipt of antimicrobials prior to specimen collection will reduce the yield of certain species and also select for more resistant organisms.	<b>No</b>	

## Note

It is recommended that this checklist is used in conjunction with the original article (9), available on the Web site of BMC Medicine at <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-019-1301-1> (DOI: <https://doi.org/10.1186/s12916-019-1301-1>). The checklist is reproduced from this article under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0; <http://creativecommons.org/licenses/by/4.0/>).

## References

1. CDC/NHSN. Identifying Healthcare-associated Infections (HAI) for NHSN Surveillance 2018. Available from: [https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc\\_identifyinghais\\_nhsncurrent.pdf](https://www.cdc.gov/nhsn/pdfs/pscmanual/2psc_identifyinghais_nhsncurrent.pdf).
2. CDC/NHSN. Surveillance Definitions for Specific Types of Infections 2018. Available from: [https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef\\_current.pdf](https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf).
3. Hossain B, Islam MS, Rahman A, Marzan M, Rafiqullah I, Connor NE, et al. Understanding Bacterial Isolates in Blood Culture and Approaches Used to Define Bacteria as Contaminants: A Literature Review. *Pediatr Infect Dis J*. 2016;35(5 Suppl 1):S45-51.
4. Hossain B, Weber MW, Hamer DH, Hibberd PL, Ahmed AS, Marzan M, et al. Classification of Blood Culture Isolates Into Contaminants and Pathogens on the Basis of Clinical and Laboratory Data. *Pediatr Infect Dis J*. 2016;35(5 Suppl 1):S52-4.
5. Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, et al. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. *Lancet Infect Dis*. 2014;14(4):341-52.
6. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268-81.
7. German GJ, Gilmour M, Tipples G, Adam HJ, Almohri H, Bullard J, et al. Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, *Acinetobacter* species and *Pseudomonas aeruginosa*. *Can Commun Dis Rep*. 2018;44(1):29-34.
8. Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. *Clin Infect Dis*. 2007;44(6):867-73.
9. Turner P, Fox-Lewis A, Shrestha P, Dance DAB, Wangrangsimakul T, Cusack TP, et al. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. *BMC Med*. 2019;17(1):70.